Categories: NewsVaccine

Here for Good: Merck’s Steadfast Commitment to Health Equity

How one employee’s upbringing and career journey have motivated her to fight inequities around the world

NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work she’s done across industries.

As a young girl growing up in central London, Agrawal saw firsthand how inequities even within her own extended family could drastically impact health outcomes.

“I watched my father’s side of the family – who lived in London – live with diabetes, but I watched my mother’s side of the family – who lived in North India – die of diabetes,” Agrawal said. “It took me a while to figure out that it was my father’s family’s access to the National Health Service that made the difference.”

That early insight propelled Agrawal into a career as an obstetrician and gynecologist before moving into public health. She first joined Merck to help launch Merck for Mothers, a global initiative to help create a world where no woman has to die while giving life. From there, she went on to a variety of roles – from lead of the company’s vaccines and contraceptives business in the U.K. to managing director of South Africa and Sub-Saharan Africa to global head of HPV vaccines. She currently serves as vice president of health equity and partnerships.

Agrawal’s work – and the passion that fuels it – continues, and she has no plans to stop.

“My purpose in life is to advance health equity. I want to be able to say that I did all I could to ensure more people could both survive and thrive because they had easier access to health.”

View original content here.

https://www.3blmedia.com/sites/default/files/2024-06/Here-for-Good-%20A-steadfast-commitment-to-health-equity_Merck_061224.mp4

View additional multimedia and more ESG storytelling from Merck & Co., Inc. on 3blmedia.com.

Contact Info:
Spokesperson: Merck & Co., Inc.
Website: https://www.3blmedia.com/profiles/merck-co-inc
Email: info@3blmedia.com

SOURCE: Merck & Co., Inc.

View the original press release on accesswire.com

View the original press release on accesswire.com

Staff

Recent Posts

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

New findings support the company's neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized…

13 hours ago

Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to…

13 hours ago

MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment

SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals…

13 hours ago

RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air

LAS VEGAS, Jan. 10, 2025 /PRNewswire/ -- RingConn, a leading smart wearable brand, is proud…

13 hours ago

1933 Industries Provides Update on Status of Filing Delay for 4th Quarterly Report and Announces Management Changes

VANCOUVER, BC / ACCESSWIRE / January 10, 2025 / 1933 Industries Inc. (the "Company" or…

13 hours ago